Skip to content

Tuesday, December 15th, 2009

FDA Approves Psoriasis Drug Stelara

September 25, 2009 by Marijke Durning, RN  
Filed under Diseases & Conditions

FDA Approves Psoriasis Drug Stelara

FDA Press Release
FDA Approves New Drug to Treat Psoriasis

The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis.
Plaque psoriasis is an immune system disorder that results in the rapid overproduction of skin cells. About 6 million people in the United States have plaque psoriasis which is characterized by thickened patches of inflamed, red skin, often covered with silvery scales.
“This approval provides an alternative treatment for people with plaque psoriasis, which can cause significant physical discomfort from pain and itching and result in poor self-image for people …read more

Psoriasis Awareness Month

August 1, 2008 by Marijke Durning, RN  
Filed under Diseases & Conditions

Psoriasis Awareness Month

August is Psoriasis Awareness month. Psoriasis is a skin disease but it can also lead to a type of arthritis called psoriatic arthritis. As with rheumatoid arthritis psoriatic arthritis causes inflammation and pain in the joints, can can cause disability.
Here are some posts regarding psoriasis:

Efalizumab for Psoriasis May Trigger Psoriatic Arthritis
Press Release: FDA Committee Unanimously Recommends Approval of Ustekinumab for Plaque Psoriasis
Press release: New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Biologic agents for treatment of psoriasis
Press release: Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
Press release: Humira (adalimumab) Receives FDA Approval For Moderate to Severe …read more

Press Release: FDA Committee Unanimously Recommends Approval of Ustekinumab for Plaque Psoriasis

Press Release: FDA Committee Unanimously Recommends Approval of Ustekinumab for Plaque Psoriasis

HORSHAM, Pa., June 17 /PRNewswire/ — Centocor, Inc. announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of ustekinumab, a new subcutaneous, investigational biologic therapy for the treatment of adult patients with moderate to severe plaque psoriasis. Ustekinumab is a new human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in the body’s regulation of immune responses and that are also believed to play an important role …read more


About Us | Advertise with us | Blog for Blisstree | Privacy Policy | Terms of Use
Get This Theme | Sitemap


All content is Copyright © 2005-2009 b5media. All rights reserved.